Dr. Hans-Peter Strebel founded Fumapharm AG with three other scientists in 1983. Its successful research led to the development of Tecfidera, a disease modifying therapy for relapsing multiple sclerosis (MS). Approximately 600,000 patients worldwide have already benefited from the therapy.
Award
- Nominated in 2023
- Winner in 2024
